Consequently, melanomas resistant to BRAF/MEK inhibitors have increased mitochondria biogenesis and metabolically switch to oxidative phosphorylation (OXPHOS) through upregulation of MITF and PGC1α [17–20]. Here, BRAF is linked to melanoma.